Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerapolturev with or without anti-PD-1 in PD-1 refractory melanoma
NCT04577807Phase 2Completed
- Sponsor
- Istari Oncology
- Start
- Nov 2020
- Primary completion
- Nov 2024
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lerapolturev in melanoma (2 arms), sponsored by Istari Oncology. Primary endpoints: Overall Response Rate at 24 months, Treatment-emergent Adverse Events at 24 months and 4 more. Started Nov 2020; status: completed.
02
Drugs
lerapolturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04577807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577807.